CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 405 enrolled
Drug / intervention
Experimental: Tezepelumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03927157
NCT03927157Phase 3Completed
CompareCT.gov

A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults With Severe Uncontrolled Asthma

AstraZeneca·interventional·Posted Apr 25, 2019·Updated Jul 1, 2025

In Brief

A Phase 3 clinical trial evaluating Experimental: Tezepelumab and Placebo for Asthma. Completed, enrolled 405 participants across 72 sites in 3 countries.

Detailed Summary

A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesChina, Philippines, South Korea
CollaboratorsAmgen

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 25, 2019
Enrollment StartJun 14, 2019
Primary CompletionMay 24, 2024
Study CompletionAug 13, 2024
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 7.2 years ago

Interventions

Experimental: Tezepelumabbiological

Tezepelumab subcutaneous injection

Placeboother

Placebo subcutaneous injection